B7-33
Frequently Bought Together
B7-33 by BeaCapra — premium research-grade compound verified to ≥99.0% purity via independent HPLC and LC-MS analysis.
Supplied as lyophilized (freeze-dried) powder in vacuum-sealed glass vials. Each batch undergoes rigorous third-party testing to ensure pharmaceutical-grade consistency and stability.
Specifications
- Purity: ≥99.0% (HPLC verified)
- Form: Lyophilized Powder
- Category: Recovery Research
- Storage: -20°C recommended, protect from light
Quality Assurance
Every BeaCapra product ships with a Certificate of Analysis (COA) documenting purity verification via HPLC and mass spectrometry. Our compounds are synthesized under strict GMP-adjacent protocols and undergo batch-level quality control.
For Research Use Only (RUO). Not intended for human consumption, therapeutic, or diagnostic use.
Research Benefits
- Relaxin Receptor Research — B7-33 is a single-chain relaxin-2 analog that activates RXFP1, the relaxin family peptide receptor 1, without requiring the native two-chain disulfide-bonded structure.
- Anti-Fibrotic Studies — B7-33 demonstrates anti-fibrotic effects in cardiac, pulmonary, and renal fibrosis models through RXFP1-mediated MMP upregulation and collagen remodeling.
- Cardiovascular Protection — Research shows B7-33 promotes vasodilation, reduces cardiac hypertrophy, and improves diastolic function in heart failure models.
- Simplified Analog — As a single-chain peptide, B7-33 is more synthetically accessible than native relaxin-2, enabling broader research applications.
Mechanism of Action
B7-33 is a simplified, single-chain peptide analog of human relaxin-2 that activates RXFP1 through a biased agonism profile.
RXFP1 Activation: B7-33 binds RXFP1 (a leucine-rich repeat-containing GPCR) and activates Gs-coupled signaling, increasing cAMP and activating downstream PKA and Akt pathways.
eNOS/NO Pathway: RXFP1 activation by B7-33 stimulates endothelial nitric oxide synthase (eNOS) via Akt phosphorylation, increasing NO production and promoting vasodilation.
MMP Regulation: B7-33 upregulates matrix metalloproteinases (MMP-2, MMP-9, MMP-13) while downregulating tissue inhibitors of metalloproteinases (TIMPs), promoting extracellular matrix remodeling and fibrosis resolution.
Anti-Fibrotic Signaling: Via Smad2/3 inhibition and TGF-β pathway antagonism, B7-33 reduces myofibroblast differentiation and collagen deposition in fibrotic tissues.
Research Protocol
For research use only.
Reconstitution
Reconstitute in sterile PBS or 20 mM sodium acetate (pH 5.0). Stock: 100 μg/mL.
Research Dosing (from published studies)
- In vivo (murine, fibrosis): 0.5-2 mg/kg/day SC or via osmotic minipump for 14-28 days.
- In vitro: 10-100 nM for fibroblast and endothelial cell assays.
- Cardiac models: Osmotic minipump delivery at 0.5 mg/kg/day for 4 weeks in isoproterenol-induced cardiac fibrosis.
Storage
Lyophilized at -20°C. Reconstituted at 2-8°C, use within 7 days.
Safety & Handling
Research Use Only.
Known Considerations
- Vasodilatory effects may cause transient hypotension; hemodynamic monitoring recommended in cardiovascular models.
- MMP upregulation is the desired anti-fibrotic mechanism but may theoretically destabilize ECM in non-fibrotic tissues at excessive doses.
- B7-33 shows biased agonism at RXFP1 compared to native relaxin-2; some signaling pathways may not be fully recapitulated.
Frequently Asked Questions
- What is B7-33?
- B7-33 is a single-chain peptide analog of human relaxin-2 that activates the relaxin receptor RXFP1. It was designed to simplify the synthesis of relaxin (normally a complex two-chain, three-disulfide peptide) while retaining key biological activities.
- How does B7-33 differ from native relaxin-2?
- Native relaxin-2 is a 53-amino acid, two-chain peptide with three disulfide bonds. B7-33 is a single-chain peptide mimicking the B-chain receptor-binding domain, making it much simpler to synthesize while retaining RXFP1 agonism.
- What is biased agonism?
- Biased agonism means B7-33 preferentially activates certain signaling pathways (e.g., cAMP, pERK) downstream of RXFP1 while having reduced activity on others. This can be an advantage for targeting specific therapeutic-relevant pathways.
- What purity is this product?
- BeaCapra B7-33 is ≥99% pure by HPLC with COA documentation.
Related formulas
Customer Reviews
Exceptional purity and fast shipping
Third-party COA verified at 99.1% purity. Arrived in 2 days with proper cold packaging. The documentation included was thorough and professional. Will be ordering again for our lab.
Best supplier I've found
After trying several suppliers, BeaCapra consistently delivers the highest quality compounds. The subscribe & save option is a great value, and their customer support team answered all my questions promptly.
Great product, COA checks out
Ran our own HPLC analysis and confirmed the purity claims. Packaging was secure and discreet. Only minor note — would love to see more size options for some of the newer compounds. Otherwise excellent.
Subscribe & save is the way to go
The 15% discount on subscription makes this the most competitive pricing I've found for research-grade compounds at this purity level. Auto-delivery every 30 days has been seamless. Highly recommend.
Exactly what our research team needed
We've been sourcing from BeaCapra for our university lab and the consistency batch-to-batch is impressive. Every order comes with a COA and the compounds are properly lyophilized. Professional operation all around.
Questions About B7-33
General Questions
Everything you need to know about BeaCapra research peptides, ordering, shipping, and our commitment to quality.
Still have questions? Our research specialists are here to help.
Contact Us